RMPBX201801: Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis

Sponsor
InvestigatorUrologyIBSAL (Other)
Overall Status
Unknown status
CT.gov ID
NCT04283032
Collaborator
Instituto de Investigación Biomédica de Salamanca (Other)
628
1
22
28.5

Study Details

Study Description

Brief Summary

Objectives: To establish if there are differences between an ultrasound-guided transrectal prostate biopsy (BPTE) and a transperineal prostatic biopsy (BPTP) with and without a multiparametric Magnetic Resonance (RMmp) in patients with clinical suspicion of prostate cancer (PC) to first prostatic biopsy in terms of:

  1. Rate of detection and diagnosis of prostate cancer.

  2. Aggressiveness of the detected tumors.

  3. Association of the marker [-2] proPSA and the prostate cancer health index (PHI) and microRNAs for the diagnosis of tumors.

  4. Adverse effects of the intervention and subjective perception of the patient: pain and degree of satisfaction, and impairment of quality of life.

  5. Cost-effectiveness analysis of the different intervention options.

Study Design: Randomized, single-blind prospective clinical study to compare four schemes:

RMmp + BPTE vs. BPTE 12 cylinders vs RMmp + BPTP vs BPTP 12 cylinders.

Study population: Patients with clinical suspicion of prostate cancer with PSA between 3-20 ng / mL and normal or abnormal rectal examination, candidates for a first prostate biopsy.

Research techniques: BPTE standard of 12 cylinders compared to RMmp previous to BPTE vs BPTP of 12 cylinders compared to BPTP with previous RMmp.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
628 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer With Different Approaches. Cost-effectiveness Analysis (RMP-BX 2018-01)
Anticipated Study Start Date :
Mar 1, 2020
Anticipated Primary Completion Date :
Jun 30, 2020
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Multiparametric magnetic resonance + transrectal biopsy

The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transrectal biopsy (BPTE)

Procedure: Multiparametric magnetic resonance
MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
Other Names:
  • Transrectal biopsy
  • Transperineal biopsy
  • Multiparametric magnetic resonance + transperineal biopsy

    The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transperineal biopsy (BPTP)

    Procedure: Multiparametric magnetic resonance
    MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
    Other Names:
  • Transrectal biopsy
  • Transperineal biopsy
  • Transrectal biopsy

    The patient underwent a transrectal biopsy (BPTE)

    Transperineal biopsy

    The patient underwent a transperineal biopsy (BPTP)

    Outcome Measures

    Primary Outcome Measures

    1. Comparation between transrectal and transperineal prostatic biopsy with o without Magnetic Resonance [6 months]

      Establish if there are differences between the transrectal and transperineal prostatic biopsy schemes in both cases with and without MRI, in patients with suspected clinical risk of prostate cancer (total PSA between 3 and 20 ng / mL, free PSA index / Total PSA less than 20% and normal or abnormal rectal examination) in terms of efficacy measured by the detection rate and tumor aggressiveness of the tumors detected, complication rates and cost analysis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    45 Years to 75 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Signature of informed consent prior to performing any of the specific procedures of the study

    • Age between 50 * - 75 years (* 45 years, if family history)

    • Patients with clinical suspicion of prostate cancer

    • Indication of a first biopsy during the study period.

    • Life expectancy greater than 10 years.

    Exclusion Criteria:
    • Patients previously randomized in the present study.

    • Patients submitted prior to a prostate biopsy.

    • Patients with a previous diagnosis of prostate cancer and / or previous prostate surgery.

    • Patients with a previous episode of acute prostatitis of infectious origin in the 3 months prior to inclusion in the study.

    • Patients with an active urinary tract infection and / or any previous pathology of severity in the 3 months prior to inclusion.

    • Impossibility of performing transrectal or transperineal biopsy and / or magnetic resonance.

    • Patients who have received hormonal treatment prior to androgen blockade in the 6 months prior to inclusion in the study.

    • History of other tumors.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Francisco Gómez Veiga Salamanca Spain 37007

    Sponsors and Collaborators

    • InvestigatorUrologyIBSAL
    • Instituto de Investigación Biomédica de Salamanca

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    InvestigatorUrologyIBSAL, MD, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
    ClinicalTrials.gov Identifier:
    NCT04283032
    Other Study ID Numbers:
    • PI18/01560
    First Posted:
    Feb 25, 2020
    Last Update Posted:
    Feb 25, 2020
    Last Verified:
    Feb 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by InvestigatorUrologyIBSAL, MD, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 25, 2020